EMD Serono, Canada
Merck KGaA, Darmstadt, Germany
Merck KGaA, Darmstadt, Germany

EMD Serono News

To view global press releases, please visit the News Releases section on our global site of the biopharmaceutical divison of Merck KGaA, Darmstadt, Germany
For corporate news of Merck KGaA, Darmstadt, Germany, please visit the media section on www.emdgroup.com.

2017/12/04EMD Serono Receives Health Canada Notice of Compliance for MAVENCLAD™ (cladribine tablets) for patients living with relapsing-remitting multiple sclerosis (RRMS)English | French
2017/10/27Merck KGaA Darmstadt, Germany Announces Recipients of €1 Million Grant for Multiple Sclerosis Innovation at ECTRIMS 2017English | French
2017/08/23EMD Serono, Canada announces sponsorship of Canadian Cancer Society’s Mudmoiselle events in OntarioEnglish | French
2017/05/31EMD Serono Canada Gives Canadians a Deeper Look into Life with Multiple Sclerosis (MS)English | French
2017/05/31Merck KGaA Darmstadt, Germany Honors World MS Day by Launching Care Partner Survey with IACOEnglish | French
2016/12/09Merck KGaA, Darmstadt, Germany, Presents New Data on the Safety and Durable Efficacy of Cladribine Tablets and Advantages of Early Treatment with Rebif® at the 2016 ECTRIMS CongressEnglish  | French
2016/03/08Merck KGaA, Darmstadt, Germany, Lifts Forecast Following Good Second QuarterRead
2016/03/08Merck KGaA, Darmstadt, Germany Receives European Medicines Agency Acceptance for Review of Marketing Authorization Application for Cladribine TabletsEnglish |  
2015/09/18Multiple Sclerosis patients join EMD Serono staff in the 2015 MS Bike Tour, to raise funds for MS ResearchRead
2015/05/25Ontario Reimburses CIS Indication for REBIF®, a First-Line Treatment for Multiple SclerosisRead
* EMD Serono, is a division of EMD Inc., Canada, a subsidiary of Merck KGaA, Darmstadt, Germany. Germany. Its North American business operates in the United States as EMD Serono, Inc. and in Canada as EMD Serono, Canada.